ISRCTN17477081 https://doi.org/10.1186/ISRCTN17477081

A study to assess the effectiveness of Roclanda (Latanoprost/Netarsudil fixed dose combination) in reducing pressure inside the eye for adults with glaucoma or ocular hypertension

Submission date 03/06/2026	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol
Registration date 18/06/2026	**Overall study status** Ongoing	[_] Statistical analysis plan [_] Results
Last Edited 04/06/2026	**Condition category** Eye Diseases	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol

Background and study aims

Glaucoma is a common eye condition that can lead to permanent vision loss if it is not treated. Ocular hypertension means raised pressure inside the eye and increases the risk of developing glaucoma. This study looks at a medicine called Roclanda, which combines two treatments, latanoprost and netarsudil. These medicines help fluid drain from the eye, lowering eye pressure. The aim of the study is to see how well this treatment works and how safe it is for people in routine NHS care who have not responded well to previous single-drug treatment

Who can participate?

Adults aged 18 years or older who have been diagnosed with primary open-angle glaucoma or ocular hypertension may take part. Participants must already have tried a single treatment to lower eye pressure that did not work well enough. They must also have been prescribed the study treatment as part of their usual care and be able to give consent to take part

What does the study involve?

This is an observational study, which means no extra treatment or hospital visits are required. Participants will receive their usual care and treatment as prescribed by their doctor. Researchers will collect information from routine clinic visits over a period of up to 3 months. The study does not change the care patients receive and does not require extra tests

What are the possible benefits and risks of participating?

Participants may benefit from receiving a treatment that could better control their eye pressure. The study may also help improve care for future patients with glaucoma or ocular hypertension. As the treatment is already approved and used in routine care, the risks are those normally linked with this medicine. These may include eye irritation or redness, but no additional risks are expected from taking part in the study itself

Where is the study run from?
The study is being carried out in NHS hospitals across England, including sites in London, Leicester, Manchester, Liverpool, York, and Newcastle

When is the study starting and how long is it expected to run for?
April 2026 to October 2026.

Who is funding the study?
Santen (UK)

Who is the main contact?
Ms Julia Martin, julia.martin@santen.com
Mr Jonathan Clarke, jonathan.clarke8@nhs.net

Contact information

Type(s)
Public, Scientific

Contact name
Ms Julia Martin

Contact details
Santen UK Ltd, Salisbury Hall
St Albans
United Kingdom
AL2 1BU
+44 1727 615110
julia.martin@santen.com

Type(s)
Principal investigator, Scientific

Contact name
Mr Jonathan Clarke

Contact details
Moorfields Eye Hospital
City Road
London
United Kingdom
EC1V 2PD
+44 2072533411
jonathan.clarke8@nhs.net

Additional identifiers

Integrated Research Application System (IRAS)
369113

Central Portfolio Management System (CPMS)
72791

Study information

Scientific Title
PRECISION - A Prospective obseRvational study to assEss the real-world effeCtiveness and tolerability of Latanoprost/NetarsudIl fixed doSe combination in reducing Intraocular pressure in adult patients with primary Open-angle glaucoma or ocular hypertensioN

Acronym
PRECISION

Study objectives
The primary objective in this study is to assess the effectiveness of LAT/NET FDC at 3 months in reducing IOP in adult patients with POAG or OHT, who did not respond sufficiently to monotherapy with a PGA or netarsudil in routine practice

The secondary objectives in this study are:
1. To assess the short-term effectiveness of LAT/NET FDC at 6 weeks in reducing intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension
2. To determine the proportion of treatment responders at 3 months
3. To describe the change in intraocular pressure following initiation of LAT/NET FDC in patients with normal-range baseline intraocular pressure of 20 mmHg or lower
4. To assess the change in eye symptoms score from baseline following LAT/NET FDC use at 3 months using the PNO425 glaucoma symptom scale questionnaire
5. To assess clinician satisfaction of LAT/NET FDC at 3 months using the PNO425 clinician assessment of treatment satisfaction and tolerability questionnaire
6. To assess the tolerability of LAT/NET FDC after 3 months of treatment using the PNO425 clinician assessment of treatment satisfaction and tolerability questionnaire
7. To describe the interval between the diagnosis of primary open-angle glaucoma or ocular hypertension and initiation of LAT/NET FDC
8. To describe the prior treatments for primary open-angle glaucoma or ocular hypertension
9. To assess the proportion of patients discontinuing LAT/NET FDC treatment and reasons for discontinuation
10. To assess the safety of LAT/NET FDC in the treatment of primary open-angle glaucoma or ocular hypertension in routine clinical practice
11. To assess the clinical signs and severity of bulbar conjunctival hyperaemia during treatment with LAT/NET FDC stratified by clinician reported aetiology
12. To describe the presence of cornea verticillata during treatment with LAT/NET FDC
13. To describe participants' socio-demographic characteristics

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 19/03/2026, London - Queen Square Research Ethics Committee (2 Redman Place Stratford, London, E20 1JQ, United Kingdom; +44 20 7104 8000; queensquare.rec@hra.nhs.uk), ref: 26/PR/0246

Primary study design

Observational

Secondary study design
Cohort study

Study type(s)

Health condition(s) or problem(s) studied
Primary open angle glaucoma and ocular hypertension

Interventions
This non-interventional study will observe participants for up to 3 months from the start of their LAT/NET FDC treatment, or until they withdraw consent, switch to another treatment, become pregnant, pass away, or are lost to follow-up. During this period, data will be collected from routine visits and usual assessments with no extra visits resulting from inclusion into the study.

Intervention Type
Other

Primary outcome(s)
1. Intraocular pressure measured using IOP measurements at Baseline, 6 weeks and 3 months

Key secondary outcome(s)

Completion date
31/10/2026

Eligibility

Key inclusion criteria
1. A diagnosis of primary open-angle glaucoma (POAG) or ocular hypertension (OHT)
2. Patient aged ≥ 18 years
3. Have previously received monotherapy with a prostaglandin analogue or netarsudil which has provided insufficient IOP reduction
4. Patients for whom the decision to initiate treatment with LAT/NET FDC was made as part of routine clinical practice and prior to study inclusion
5. Signed informed patient consent before the start of data collection

Healthy volunteers allowed
No

Age group
Mixed

Lower age limit
18 Years

Upper age limit
110 Years

Sex
All

Total final enrolment
0

Key exclusion criteria
1. Previously received combination therapy of topical IOP-lowering medications (including a fixed dose combination)
2. Patient is pregnant, and/or lactating, or planning pregnancy in the following 3 months
3. Contraindications as listed in the SmPC
4. Participation in an investigational programme with interventions outside of routine clinical practice within 30 days prior to enrolment
5. Previous treatment of the study eye with laser in the last 90 days prior to enrolment
6. Patient is listed for laser treatment in the study eye within the next 90 days after enrolment
7. Has a condition or be in a situation that, in the Investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's study participation

Date of first enrolment
14/04/2026

Date of final enrolment
31/07/2026

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Leicester Royal Infirmary
Infirmary Square
Leicester
England
LE1 5WW

Study participating centre
Manchester Royal Eye Hospital
Oxford Road
Manchester
England
M13 9WL

Study participating centre
Liverpool University Hospitals NHS Foundation Trust
Royal Liverpool University Hospital
Prescot Street
Liverpool
England
L7 8XP

Study participating centre
York and Scarborough Teaching Hospitals NHS Foundation Trust
York Hospital
Wigginton Road
York
England
YO31 8HE

Study participating centre
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
England
NE1 4LP

Study participating centre
Moorfields Eye Hospital (city Road Campus)
162 City Road
London
England
EC1V 2PD

Sponsor information

Organisation
Santen (United Kingdom)

ROR
https://ror.org/038kcjb09

Funder(s)

Funder type

Funder Name
Santen

Alternative Name(s)
Santen Pharmaceutical

Funding Body Type
Private sector organisation

Funding Body Subtype
For-profit companies (industry)

Location
Japan

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available